Silexion Therapeutics Corp Ordinary Shares
Here’s whether Silexion Therapeutics Corp Ordinary Shares (SLXN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 42 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-22.04% over 10 days); weak 1-year return of -96.6%; 3-month momentum negative (-66.7%); rising volume on a downtrend (distribution, 2.98x avg). Currently 97.8% off its 52-week high. Score: -5/7.
SLXN is trading below its 200-day MA ($2.75) — a key warning sign the longer-term trend is under pressure. An RSI of 42.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -96.6% compares to +27.9% for SPY (trailed the market by 124.5%). The current 97.8% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.